Research to Reality: Transformation in Life Sciences
Date: May 16th & May 17th
Live Event: 9:00 AM – 12:00 PM EDT
Replay: 9:00 PM – 12 AM EDT
Research to Reality: Transformation in Life Sciences
Date: May 16th & May 17th
Live Event: 9:00 AM – 12:00 PM EDT
Replay: 9:00 PM – 12 AM EDT
KPMG hosted the third annual Global Life Sciences Summit on May 16 and 17, 2023, covering the most immediate and topical issues facing life sciences executives on their transformation journey. In the thriving life sciences industry, inclusive and digital health takes center stage and defines corporate purpose. This is driven by changing patient needs, demand for skilled talent, and emerging technology.
This years’ Summit brought together founders, pioneers and innovators from the top organizations and companies around the world to collaborate on the future of the pharmaceutical, biomedical, and medical device industries and examine the changes happening in the field. More than 1500 industry experts and KPMG leaders joined this summit discussing the future of life sciences from an industrial and economic standpoint.
Highlights included discussions on the expanding role of Artificial Intelligence and Chat GPT, the FTC Anti-Trust battle with tech giants like Facebook, modern ESG solutions and responsible sourcing, exciting innovations in women’s health amidst the growth of women working in technology, data privacy and how it affects patient safety, the role of Precision Medicine in advanced treatment of diseases like cancer and dementia, and a deep dive into Avalon, the world’s first healthcare Metaverse.
Set on a virtual platform over two days and six sessions, this dynamic and inspirational event allowed participants to share different perspectives, explore new approaches and gain invaluable insights. The sessions include pre-recorded “fire-side chats” along with a live chat function, providing the opportunity for attendees to engage in Q & A with KPMG’s subject matter experts during the live viewing.
GLSS Session 1 Summary | Industry & Economic Outlook
An introduction to the Summit and discussion on the future of life sciences from an industrial and economic standpoint
GLSS Session 2 Summary | Deals, M&A, Alliances
Conducting deals in an era of greater portfolio specialization
GLSS Session 3 Summary | Advancing ESG Solutions
Initiatives to support the health of people and the planet
GLSS Session 4 Summary | Data science and technology
Digital transformation, innovation and data as an asset, metaverse
GLSS Session 5 Summary | Connected Enterprise
Streamlining supply chain and data privacy compliance to benefit all dimensions of the healthcare ecosystem
GLSS Session 6 Summary | Future of Life Sciences
Advancements in precision medicine affecting innovation across all therapeutic areas, in markets around the world
Tuesday, May 16th 2023 | |||
---|---|---|---|
Masters of Ceremony: Anna Marie Detert, Partner, Healthcare and Life Sciences, KPMG UK Guillaume Favier, Strategy Partner, Healthcare and Life Sciences, KPMG UK | |||
Time | Session | Speaker(s) | KPMG Host |
9:00 am – 9:55 am | Session 1: Industry and Economic Outlook | ||
1A: Healthcare Outlook | Anna van Poucke, Global Head of Healthcare at KPMG International | ||
1B: Economic Outlook | Yael Selfin, Chief Economist, KPMG UK | ||
1C: Digital Healthcare Solutions | Dr. Alexander Condoleon, Vice President, Head of Digital Healthcare, Sanofi | Alison Little, Principal, Advisory KPMG US | |
10:00 – 10:55 a.m. | Session 2: Deals, M & A, Alliances | ||
| 2A: Connectivity, Trust, Collaboration – a new way for partnerships | Jean-Christophe Tellier, CEO at UCB
|
Kristin Pothier, Global Life Sciences Deal Advisory and Strategy Leader, KPMG US
|
| 2B: FTC Antitrust Battle with Facebook and the impact on future deals in Life Sciences | Arman Oruc, Partner at Goodwin, Co-Chair, Anti-Trust, Goodwin | Jeff Stoll, PhD, Partner, National Leader Life Sciences, Strategy Consulting, KPMG US
|
11:00 - 11:55 a.m. | Session 3: Advancing ESG Solutions: Initiatives to Support the Health of People and Planet | ||
| 3A: Women in Technology | Michelle Greene, Executive Vice President and Chief Information Officer, Cardinal Health | Fiona Thomas, Chief Medical Officer, KPMG UK |
| 3B: Women’s Health Innovation | Dr. Sandy Milligan, Head of Research and Development, Organon | Fiona Thomas, Chief Medical Officer, KPMG UK |
| 3C: Responsible Sourcing | Kevin Nelson, SVP & CPO, Becton Dickinson | Blythe Chorn, Managing Director, Consulting, ESG Leader, KPMG US |
3D: Health Equity | Rady Johnson, Chief Compliance, Quality & Risk Officer, Pfizer, Inc. | Melissa Taylor, Partner, Audit, KPMG US |
Wednesday, May 17th 2023 | |||
---|---|---|---|
Time | Session | Speaker(s) | KPMG Host |
9:00 am – 9:55 am | Session 4: Data Science and Technology | ||
4A: Data as an asset: Explore how creating a data asset enables competitive differentiation and strategic advantage | Rachel Lin, Regional Commercial Director, Janssen Asia Pacific Freddie Yi Yu, Director & Data Scientist, Janssen Asia Pacific Thomas Halliday, LifeScience & Healthcare, Customer Vertical Leader, Clarivate | Anastasia Miros, Director, Healthcare and Life Sciences, KPMG Asia Pacific | |
4B: Customer and employee digital transformation | Hank Yang, Managing Director, Healthcare and Life Sciences, KPMG US Roni Kopelman, Managing Director, Human Capital Advisory, KPMG US | ||
4C: Avalon: The world's first healthcare metaverse | Shafi Ahmed, Chief Medical Officer, Medical Realities | Justin Hoss, Principal Advisory, KPMG US | |
10:00 – 10:55 a.m. | Session 5: Connected Enterprise | ||
| 5A: Data privacy | Brian Cincera, SVP & Chief Information Security Officer, Pfizer, Inc. | Caroline Rivett, Cyber in Life Sciences Global Lead, KPMG, UK |
5B: Innovation in Compliance | John Gitas, Principal, Advisory, Forensic, KPMG US Matthew Colford, Director, Healthcare and Life Sciences Advisory, KPMG US | ||
5C: Patient Safety and Quality | Steve C de Baca, Chief Patient Safety and Quality Officer, Philips | Rajesh Misra, Principal, Life Sciences Operations Advisory, KPMG US | |
11:00 am – 11:55 am | Session 6: Future of Life Sciences | ||
| 6A: Roadblocks on the path to Precision Medicine | Luca Dezzani, VP US Oncology Medical Affairs, Johnson & Johnson | Alasdair Milton, Managing Director, Healthcare & Life Sciences, KPMG US |
| 6B: The role of the patient in the evolving patient journey of Precision Medicine in Neurodegenerative Diseases | Pearl Pugh, President, Neuroscience, Johnson & Johnson Dr. Howard Fillit, Co-Founder and Chief Science Officer at the Alzheimer's Drug Discovery Foundation | Varun Renjen, MD Managing Director, Life Sciences Deal Advisory and Strategy, KPMG US |
Shafi Ahmed
Brian Cincera
Dr. Alexander Condoleon
Terri Conneran
Steve C de Baca
Luca Dezzani
Dr. Howard Fillit
Michelle Greene
Thomas Halliday
Rady Johnson
Rachel Lin
Dr. Sandy Milligan
Kevin Nelson
Arman Oruc
Pearl Pugh
Jean-Christophe Tellier
Freddie Yi Yu
looking back
The 2022 Global Life Sciences Summit brought together industry leaders and our experts from around the world to discuss the future of the pharmaceutical, biomedical, and medical device industries. This virtual summit allowed viewers to share different perspectives and explore new approaches to help chart a future course.